These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20651308)

  • 1. Growth of REMS challenges FDA, stakeholders.
    Traynor K
    Am J Health Syst Pharm; 2010 Aug; 67(15):1221-2. PubMed ID: 20651308
    [No Abstract]   [Full Text] [Related]  

  • 2. Assuring safety of inherently unsafe medications: the FDA risk evaluation and mitigation strategies.
    Nelson LS; Loh M; Perrone J
    J Med Toxicol; 2014 Jun; 10(2):165-72. PubMed ID: 24414251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Evaluation and Mitigation Strategy (REMS): FDA Perspective on What Physicians Need to Know.
    Slatko GH
    Am Fam Physician; 2015 Nov; 92(9):771-2. PubMed ID: 26554468
    [No Abstract]   [Full Text] [Related]  

  • 4. [Under FDA scrutiny: 19 drugs monitored for safety concerns].
    Sabourin G
    Perspect Infirm; 2010; 7(2):44-5. PubMed ID: 21744604
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA Regulation of Prescription Drugs.
    Gassman AL; Nguyen CP; Joffe HV
    N Engl J Med; 2017 Feb; 376(7):674-682. PubMed ID: 28199811
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA Adds Online REMS Table.
    Aschenbrenner DS
    Am J Nurs; 2017 Nov; 117(11):21. PubMed ID: 29076851
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.
    Shane R
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S6-S12. PubMed ID: 19966079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.
    Botelho SF; Martins MA; Vieira LB; Reis AM
    J Clin Pharmacol; 2017 Apr; 57(4):493-499. PubMed ID: 27568487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk evaluation and mitigation strategies (REMS): educating the prescriber.
    Nicholson SC; Peterson J; Yektashenas B
    Drug Saf; 2012 Feb; 35(2):91-104. PubMed ID: 22171604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA drug safety communications: a narrative review and clinical considerations for older adults.
    Marcum ZA; Vande Griend JP; Linnebur SA
    Am J Geriatr Pharmacother; 2012 Aug; 10(4):264-71. PubMed ID: 22683398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications.
    Meyer BM
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S3-5. PubMed ID: 19966078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA's monitoring of postmarketing studies probed.
    Young D
    Am J Health Syst Pharm; 2006 Aug; 63(16):1485-6. PubMed ID: 16896075
    [No Abstract]   [Full Text] [Related]  

  • 14. Doing nothing is doing something: primary care antidepressant treatment in the era of FDA boxed warnings.
    Lacy BW; Baron DA; Goin MK; Gross LS; Slaby AE; Sumner CR
    J Am Osteopath Assoc; 2013 Feb; 113(2):117-9. PubMed ID: 23412671
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceuticals and medical devices: medical devices.
    ; Berry MD
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-38. PubMed ID: 22403842
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Berry MD
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA should tighten post-marketing surveillance of prescription drugs, says Institute of Medicine.
    Roehr B
    BMJ; 2012 May; 344():e3104. PubMed ID: 22549070
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed.
    Nicholson S; Peterson J; Yektashenas B
    Expert Opin Drug Saf; 2012 Mar; 11(2):299-314. PubMed ID: 22233294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proceedings of a Workshop: US Food and Drug Administration-International Society of Pharmacometrics Model-Informed Drug Development in Oncology.
    Bruno R; Jin JY; Maxfield K; Milligan L; Liu C; Wang Y; McKee AE; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):81-83. PubMed ID: 30951201
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.